GlassScriptPhysician profile
Silpa C Reddy
NPI 1003855818
$12,657.34
in general payments reported to CMS, 2019-2025
59 companies · $2,629 in 2025
The $2,629 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $750 · 2020: $387 · 2021: $621 · 2022: $869 · 2023: $3,357 · 2024: $4,045 · 2025: $2,629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,181 · Consulting Fee: $2,820 · Education: $29.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,181.13 |
| Consulting Fee | $2,820.00 |
| Education | $29.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,888.88 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Janssen Scientific Affairs, LLC | $1,515.10 | 2024-2025 | Darzalex, Rybrevant |
| Pfizer INC. | $1,042.57 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $588.89 | 2019-2025 | |
| Genentech USA, INC. | $508.82 | 2019-2025 | Polivy, Lunsumio, Venclexta |
| Astrazeneca Pharmaceuticals LP | $483.91 | 2019-2025 | Lynparza, Enhertu, Tagrisso |
| Seagen INC. | $476.05 | 2019-2023 | Adcetris, Padcev, Tukysa |
| Celgene Corporation | $474.55 | 2019-2025 | Reblozyl, Pomalyst, Opdivo |
| Merck Sharp & Dohme LLC | $420.48 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Exelixis INC. | $351.02 | 2019-2025 | Cabometyx |
| Beigene USA, INC. | $312.78 | 2021-2025 | Brukinsa, Tevimbra |
| Takeda Pharmaceuticals U.S.A., INC. | $304.66 | 2021-2025 | Alunbrig, Ninlaro, Iclusig |
| Eisai INC. | $276.91 | 2019-2025 | |
| Incyte Corporation | $274.42 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Astellas Pharma US INC | $266.21 | 2020-2025 | Padcev, Vyloy, Xtandi |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Silpa Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.